Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -41.15% is 10% above its 5-year average of -45.82%, around the middle of its 5-year range (-90.57%–-13.66%).
21.04% above its 12-month average of -52.11%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.58%.
RETURN ON ASSETS (ROA)
-41.15%
RETURN ON ASSETS (ROA) AVG TTM
-52.11%
RETURN ON ASSETS (ROA) AVG 3Y
-46.68%
RETURN ON ASSETS (ROA) AVG 5Y
-45.82%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+21.04%
CURRENT VS 3Y AVG
+11.86%
CURRENT VS 5Y AVG
+10.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-27.54%
vs the sector median at left
Whitehawk Therapeutics Inc
Market Cap
$205.80M
Return on Assets (ROA)
-41.15%
TTM Avg
-52.11%
3Y Avg
-46.68%
5Y Avg
-45.82%
Market Cap
$207.27M
Return on Assets (ROA)
18.34%
TTM Avg
16.50%
3Y Avg
12.68%
5Y Avg
11.55%
Market Cap
$208.31M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$209.91M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$210.41M
Return on Assets (ROA)
-55.47%
TTM Avg
-12.81%
3Y Avg
-16.15%
5Y Avg
-23.71%
Market Cap
$200.96M
Return on Assets (ROA)
-58.10%
TTM Avg
-37.08%
3Y Avg
-28.02%
5Y Avg
-25.91%
Market Cap
$210.98M
Return on Assets (ROA)
-79.86%
TTM Avg
-75.29%
3Y Avg
-50.35%
5Y Avg
-41.02%
Market Cap
$198.33M
Return on Assets (ROA)
-48.31%
TTM Avg
-30.88%
3Y Avg
-28.11%
5Y Avg
-28.36%
Market Cap
$197.87M
Return on Assets (ROA)
-36.44%
TTM Avg
-34.11%
3Y Avg
-41.19%
5Y Avg
-34.63%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Whitehawk Therapeutics Inc (WHWK) | $205.80M | -41.15% | -52.11% | -46.68% | -45.82% |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 18.34% | 16.50% | 12.68% | 11.55% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | 25.43% | 5.08% | -10.27% | -14.74% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -55.47% | -12.81% | -16.15% | -23.71% |
| Alector, Inc. (ALEC)vs › | $200.96M | -58.10% | -37.08% | -28.02% | -25.91% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -79.86% | -75.29% | -50.35% | -41.02% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | -48.31% | -30.88% | -28.11% | -28.36% |
| Exagen Inc. (XGN)vs › | $197.87M | -36.44% | -34.11% | -41.19% | -34.63% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 15.00% | 14.43% | -2.68% | -18.26% |
ROA
-41.1%
ROE
-43.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -13.66% |
| 2024-12-31 | -90.57% |
| 2023-12-31 | -49.66% |
| 2022-12-31 | -32.85% |
| 2021-12-31 | -69.72% |
| 2020-12-31 | -18.48% |
| 2019-12-31 | -73.57% |
